SK bioscience

SK bioscience is a vaccine company that became independent from SK Chemicals in 2018, building on a foundation in vaccine development that began in 2008. As part of the SK Group, a major South Korean conglomerate, SK bioscience focuses on promoting human health through its mission of "from prevention to cure." The company has established itself as a significant player in the vaccine industry, particularly during the COVID-19 pandemic. The company offers a variety of services centered on vaccine development and manufacturing. It operates a modern manufacturing facility in Andong, Korea, and has a dedicated R&D center that supports innovative vaccine development. SK bioscience has developed several vaccines, including SKYCellflu for influenza, SKYZoster for shingles, and SKYVaricella for varicella, all of which have received prequalification from the World Health Organization. Additionally, the company collaborates with global partners like Sanofi and MSD to enhance its vaccine offerings and contribute to public health initiatives.